ABSTRACT
Mild to moderate Alzheimer’s disease (AD) is that disease stage where cognitive, functional and increasingly the behavioural symptoms affect everyday life. By this stage the diagnosis can generally be made clinically with considerable confidence. Although biological markers that are in development may help diagnostically in the future, they still have not found their way into routine clinical practice. At this point in the disease continuum, approved AD therapies allow a standard of care for all patients and should be offered to those who have not yet been treated. Many patients will indeed not yet have been commenced on therapy as their clinician has been awaiting a more certain diagnosis.
